Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Net Cash Flow (2020 - 2025)

Historic Net Cash Flow for Barinthus Biotherapeutics (BRNS) over the last 6 years, with Q3 2025 value amounting to -$10.3 million.

  • Barinthus Biotherapeutics' Net Cash Flow rose 4242.73% to -$10.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$29.7 million, marking a year-over-year increase of 5107.41%. This contributed to the annual value of -$27.7 million for FY2024, which is 4919.95% up from last year.
  • Latest data reveals that Barinthus Biotherapeutics reported Net Cash Flow of -$10.3 million as of Q3 2025, which was up 4242.73% from -$18.1 million recorded in Q2 2025.
  • Barinthus Biotherapeutics' Net Cash Flow's 5-year high stood at $113.5 million during Q1 2021, with a 5-year trough of -$20.2 million in Q4 2021.
  • Its 5-year average for Net Cash Flow is $1.7 million, with a median of -$11.2 million in 2023.
  • Over the last 5 years, Barinthus Biotherapeutics' Net Cash Flow had its largest YoY gain of 888303.21% in 2021, and its largest YoY loss of 29652.08% in 2021.
  • Barinthus Biotherapeutics' Net Cash Flow (Quarter) stood at -$20.2 million in 2021, then soared by 43.21% to -$11.4 million in 2022, then plummeted by 68.99% to -$19.3 million in 2023, then skyrocketed by 170.55% to $13.6 million in 2024, then plummeted by 175.3% to -$10.3 million in 2025.
  • Its last three reported values are -$10.3 million in Q3 2025, -$18.1 million for Q2 2025, and -$14.9 million during Q1 2025.